Endophthalmitis symposium at EURETINA

Endophthalmitis symposium at EURETINA
Leigh Spielberg
Leigh Spielberg
Published: Thursday, September 20, 2018
Endophthalmitis continues to lurk in the back of every ophthalmologist’s mind as the most dreaded of all postoperative and post-injection complications. This was evident in the large turnout for the EURETINA Symposium, “Controversies in the Management of Endophthalmitis,” held yesterday morning at the 18th EURETINA Congress. Hosted by the FRIENDS (French Institutional Endophthalmitis Study) Group, the symposium approached several of the most difficult topics in the current management of endophthalmitis: What is the best timing for injection of antibiotics? (As early as possible.) Should adjunctive intravitreal corticosteroids be used? (No.) Is vitrectomy beneficial? (Yes, in selected cases). What about endoscopic assistance during vitrectomy? (Can be very helpful.) Prof Jan van Meurs, Rotterdam Eye Hospital, The Netherlands, presented the results of his group’s recently published study on the potential benefit of intravitreal dexamethasone injection in addition to intravitreal antibiotics. As Prof Catherine Creuzot-Garcher, University Hospital of Dijon, France, pointed out later in the symposium, there are several rationales for steroid use: limitation of leucocyte recruitment, stabilisation of the blood-retinal barrier, modification of the expression of inflammatory cytokines and stimulation of production of cytoprotectants. However, these theoretical benefits were not borne out in Prof van Meurs’ clinical trial. “Our study reported good final outcomes for most patients who received only early intravitreal injections with antibiotics, and there was no added benefit by adding intravitreal dexamethasone,” he said, commenting on his group’s double-blind, prospective, multicentre, randomised, placebo-controlled trial that included 167 patients. Prof van Meurs stressed that the most important factor in achieving good outcomes was earlier treatment.
Tags: retina
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...